zika
viru
zikv
mosquitotransmit
flaviviru
caus
microcephali
fetus
newborn
infant
associ
guillianbarr
syndrom
adult
sinc
first
discoveri
sick
rhesu
macaqu
zika
forest
uganda
zikv
expand
adapt
human
popul
across
broader
geograph
frontier
notabl
recent
unpreced
outbreak
america
caribbean
southeast
asia
invas
mosquito
speci
aed
aegypti
although
underli
biolog
ecolog
mechan
remain
unclear
high
preval
mosquito
speci
coupl
climat
chang
like
fuel
global
spread
epidem
rais
seriou
concern
pandem
potenti
zikv
near
futur
neutral
antibodi
major
compon
protect
immun
viral
infect
human
polyclon
natur
exert
function
complex
mixtur
mab
target
crucial
epitop
viral
envelop
glycoprotein
identifi
neutral
mab
recogn
epitop
therefor
becom
first
crucial
step
better
understand
protect
antibodi
respons
develop
antibodybas
therapi
vaccin
human
infect
zikv
dengu
viru
denv
flavivirus
surfac
envelop
glycoprotein
e
mediat
viral
infect
major
target
neutral
antibodi
matur
virion
monom
e
glycoprotein
pack
headtotail
homodim
zika
viru
zikv
emerg
mosquitotransmit
flaviviru
share
consider
degre
homolog
dengu
viru
denv
examin
longitudin
antibodi
respons
zikv
natur
infect
convalesc
individu
decompos
antibodi
recognit
didii
diii
e
glycoprotein
show
develop
human
follow
spatiotempor
hierarchi
plasma
bind
didii
appear
peak
wane
earli
infect
extens
crossreact
didii
denv
bind
diii
howev
peak
earli
persist
month
infect
without
detect
crossreact
diii
denv
clear
trend
increas
diiispecif
neutral
activ
observ
cours
infect
mab
isol
earli
infect
larg
didii
specif
weakli
neutral
highli
crossreact
denv
later
infect
divers
recognit
potent
neutral
zikv
specif
potent
neutral
mab
target
diii
provid
protect
mice
lethal
zikv
infect
could
therefor
serv
promis
candid
antibodybas
therapi
prevent
dynam
featur
unveil
assist
us
better
understand
pathogenesi
zikv
infect
inform
ration
design
vaccin
individu
subunit
e
glycoprotein
consist
domain
di
dii
diii
interconnect
flexibl
hing
diii
believ
contribut
viral
attach
dii
trigger
fusion
viral
target
cell
membran
analysi
mab
zikvinfect
human
mice
indic
recognit
differ
domain
associ
distinct
neutral
activ
vitro
protect
capac
anim
model
gener
mab
diii
type
specif
potentneutr
protect
wherea
diii
crossreact
poorli
neutral
markedli
enhanc
infect
vivo
zikv
infect
also
elicit
antibodi
recogn
complex
quaternari
epitop
compos
one
domain
e
glycoprotein
flaviviru
infect
howev
develop
neutral
antibodi
zikv
crossreact
denv
natur
infect
remain
larg
unknown
examin
kinet
antibodi
respons
zikv
natur
infect
convalesc
individu
sequenti
evalu
bind
specif
neutral
activ
polyclon
plasma
isol
mab
b
cell
reveal
complex
dynam
featur
antibodi
respons
develop
gener
plasma
bind
diii
appear
peak
wane
earli
week
infect
extens
crossreact
didii
denv
contrast
diii
peak
persist
extend
period
without
detect
crossreact
diii
denv
clear
trend
increas
diiispecif
neutral
activ
observ
cours
infect
although
notabl
proport
neutral
activ
account
presum
due
antibodi
recogn
complex
quaternari
epitop
compos
one
domain
e
glycoprotein
furthermor
mab
isol
earli
infect
larg
direct
diii
weakli
neutral
zikv
strongli
crossneutr
howev
mab
later
infect
divers
recognit
potent
neutral
without
detect
crossreact
final
diiispecif
mab
isol
day
onset
symptom
provid
protect
mice
lethal
zikv
infect
diiispecif
mab
isol
day
fail
taken
togeth
studi
unveil
dynam
featur
antibodi
respons
zikv
natur
infect
potent
neutral
mab
identifi
provid
promis
candid
antibodybas
intervent
also
inform
epitopefocus
vaccin
design
develop
studi
dynam
antibodi
respons
natur
infect
collect
longitudin
blood
sampl
zikvinfect
subject
return
china
travel
sever
affect
south
american
countri
venezuela
surinam
infect
statu
confirm
revers
transcript
pcr
rtpcr
zikv
rna
multipl
serum
saliva
urin
sampl
use
commerci
avail
elisa
kit
diagnosi
zikv
infect
fulllength
elisa
differenti
zikv
infect
supplement
figur
supplement
materi
avail
onlin
articl
http
doi
show
studi
subject
posit
zikv
chikungunya
viru
denv
tickborn
enceph
viru
tbev
yellow
fever
viru
yfv
japanes
enceph
viru
jev
west
nile
viru
wnv
total
sequenti
plasma
sampl
collect
patient
day
three
day
onset
symptom
serial
dilut
made
appli
elisa
plate
coat
e
glycoprotein
zikv
produc
mammalian
cell
bind
activ
detect
antihuman
igg
secondari
antibodi
express
optic
densiti
od
nm
antibodi
becam
detect
day
gradual
increas
day
reach
peak
day
figur
upper
panel
ensu
day
appreci
declin
antibodi
titer
notic
remain
fairli
high
throughout
interestingli
similar
trend
antibodi
respons
also
found
e
glycoprotein
suggest
substanti
level
crossreact
antibodi
zikvinfect
patient
figur
upper
panel
antibodi
bind
zikv
crossreact
follow
similar
pattern
although
crossreact
appear
profound
figur
lower
panel
patient
infect
zikv
without
denv
substanti
level
crossreact
must
due
sequenc
structur
share
zikv
denv
supplement
figur
addit
set
plasma
sampl
also
evalu
neutral
activ
zikv
crossreact
similar
bind
antibodi
neutral
antibodi
also
demonstr
compar
dynam
zikv
although
neutral
zikv
effici
crossneutr
figur
precipit
drop
neutral
activ
zikv
found
day
although
reason
level
crossneutr
remain
detect
figur
lower
panel
domainspecif
antibodi
respons
natur
infect
also
studi
dynam
antibodi
respons
domainspecif
e
glycoprotein
express
yeast
surfac
yeast
clone
display
diii
diii
zikv
construct
incub
sequenti
plasma
sampl
monitor
chang
antibodi
specif
time
diiispecif
antibodi
bare
detect
day
reach
peak
intens
day
follow
gradual
declin
day
diminish
neglig
level
day
figur
upper
panel
diiispecif
antibodi
howev
becam
detect
day
reach
peak
day
persist
day
despit
notic
declin
antibodi
intens
figur
upper
panel
antibodi
intens
significantli
lower
display
didii
diii
figur
lower
panel
howev
similar
delay
peak
intens
diii
also
found
compar
diii
interestingli
set
plasma
sampl
analyz
diii
diii
crossbind
exclus
target
diii
irrespect
time
point
cours
infect
supplement
figur
suggest
crossbind
e
glycoprotein
figur
larg
mediat
diii
recognit
fact
tempor
chang
crossbind
highli
correl
bind
e
glycoprotein
well
neutral
activ
zikv
figur
peak
crossbind
denv
diii
therefor
week
behind
peak
homolog
recognit
zikv
didii
indic
exist
antibodi
share
well
differenti
recognit
denv
diii
zikv
diii
domainspecif
antibodi
deplet
plasma
bind
neutral
confirm
diiiand
diiispecif
plasma
antibodi
activ
conduct
domainspecif
antibodi
deplet
experi
specif
plasma
sampl
absorb
multipl
round
zikv
diiiand
diiispecif
yeast
clone
analyz
bind
neutral
activ
shown
supplement
figur
deplet
zikv
diiispecif
bind
antibodi
result
elimin
crossbind
diii
bind
zikv
diii
remain
unaffect
hand
deplet
zikv
diiispecif
antibodi
neglig
effect
crossbind
diii
supplement
figur
result
clearli
indic
diii
respons
crossbind
activ
zikv
next
measur
impact
domainspecif
deplet
plasma
neutral
activ
four
sequenti
plasma
sampl
substanti
neutral
activ
analyz
absorpt
shown
figur
increas
contribut
diiispecif
neutral
activ
found
zikv
cours
infect
day
day
day
way
day
crossneutr
activ
affect
interestingli
sizabl
portion
neutral
activ
zikv
remain
despit
diii
deplet
presum
due
diii
recogn
complex
quaternari
epitop
compos
one
domain
e
glycoprotein
test
hypothesi
compar
plasmaneutr
activ
absorpt
zikv
di
iispecif
yeast
clone
surpris
despit
complet
deplet
zikv
diii
bind
crossbind
antibodi
supplement
figur
neutral
activ
zikv
crossneutr
activ
remain
larg
unchang
particular
later
sampl
figur
part
zikv
could
due
diiispecif
neutral
antibodi
crossneutr
must
aris
recogn
complex
diii
epitop
zikv
diiispecif
yeast
clone
could
express
present
word
bind
antibodi
zikv
diiiand
diiispecif
yeast
clone
repres
use
meaning
biomark
plasma
antibodi
respons
mean
complet
particular
come
neutral
activ
addit
approach
isol
character
monoclon
antibodi
certainli
strengthen
compliment
plasmabas
profil
isol
sequenc
analysi
mab
b
cell
character
dynam
antibodi
respons
set
isol
mab
plasmablast
igd
igm
high
memori
igd
igm
low
b
cell
greater
emphasi
place
due
stronger
antibodi
respons
avail
larger
number
sampl
total
mab
success
obtain
figur
first
conduct
phylogenet
analysi
amino
acid
sequenc
antibodi
variabl
region
identifi
coupl
domin
cluster
figur
exampl
tree
built
upon
heavi
chain
variabl
region
left
panel
famili
contain
total
mab
isol
similar
domin
famili
also
found
separ
studi
famili
zikv
diii
specif
didii
didii
crossreact
see
remain
belong
famili
belong
respect
bind
specif
much
divers
compar
cluster
see
tree
construct
upon
light
chain
variabl
region
right
panel
antibodi
cluster
gener
mirror
heavi
chain
variabl
region
correspond
famili
respect
find
suggest
mab
within
cluster
deriv
common
antibodi
ancestor
interest
note
mab
isol
earli
infect
appear
diverg
germlin
sequenc
later
mab
figur
thorough
studi
would
requir
valid
observ
ideal
context
specif
antigen
even
specif
epitop
final
except
mab
longer
region
heavi
chain
percent
contribut
indic
dark
gray
calcul
compar
neutral
activ
plasma
sampl
treat
zikv
diii
diii
irrelev
yeast
clone
correspond
light
chain
length
heavi
chain
rang
amino
acid
light
chain
rang
amino
acid
bind
neutral
activ
isol
mab
next
measur
bind
e
glycoprotein
zikv
produc
mammalian
cell
elisa
among
mab
zikv
e
glycoprotein
specif
remain
crossreact
e
glycoprotein
figur
figur
fairli
weak
crossbind
compar
rest
control
mab
previous
report
other
demonstr
expect
specif
mab
subject
plaqu
reduct
neutral
test
zikv
figur
figur
potent
neutral
mab
zikv
specif
binder
zikv
e
glycoprotein
halfmaxim
inhibitori
concentr
ic
respect
remain
mab
show
modest
even
ic
neutral
activ
strikingli
mab
except
demonstr
potent
crossneutr
activ
ic
rang
compar
isol
denvinfect
patient
fail
show
cross
neutral
addit
cross
neutral
appear
effect
averag
ic
former
latter
interest
note
potent
neutral
mab
deriv
memori
b
cell
collect
day
onset
symptom
wherea
almost
antibodi
poorli
neutral
crossreact
plasmablast
memori
b
cell
preced
sampl
figur
figur
previous
shown
control
mab
demonstr
impress
crossneutr
activ
wherea
specif
neutral
zikv
epitop
map
isol
mab
use
two
method
determin
epitop
specif
isol
mab
one
bind
yeast
clone
display
diii
diii
zikv
pairwis
competit
measur
use
surfac
plasmon
reson
spr
base
unequivoc
bind
pattern
shown
figur
epitop
specif
isol
mab
broadli
classifi
major
categori
didii
diii
didiidiii
figur
mab
isol
first
day
fell
didii
categori
figur
figur
four
mab
day
rather
diverg
epitop
specif
belong
didii
belong
diii
belong
didiidiii
didii
didiidiii
furthermor
mab
zikv
didii
categori
strongli
crossreact
didii
although
margin
detect
crossreact
didii
reason
current
uncertain
supplement
figur
b
detect
crossreact
either
high
degre
crossrecognit
mab
level
may
provid
explan
strong
crossreact
found
polyclon
plasma
sampl
figur
supplement
figur
next
confirm
epitop
determin
spacial
relationship
pairwis
competit
use
spr
specif
repres
mab
categori
didii
diii
didiidiii
select
base
cluster
phylogenet
tree
sequenc
similar
heavi
light
chain
region
figur
select
mab
within
categori
pair
sequenti
appli
captur
zikv
e
glycoprotein
sensor
chip
monitor
addit
bind
determin
whether
mab
recogn
separ
close
situat
epitop
shown
summar
supplement
figur
isol
mab
occupi
fairli
divers
distinct
epitop
among
categori
didii
recogn
similar
overlap
epitop
distinct
recogn
figur
categori
diii
compet
posit
control
suggest
epitop
locat
later
ridg
region
within
diii
furthermor
competit
found
categori
didiidiii
howev
compet
repres
mab
categori
didii
compet
list
diii
supplement
figur
result
confirm
epitop
locat
junctur
region
didii
diii
lean
toward
toward
diii
exact
epitop
mab
would
requir
futur
structur
mutagenesi
studi
protect
efficaci
mice
among
isol
mab
select
test
protect
efficaci
vivo
larg
due
distinct
biolog
genet
featur
associ
time
point
initi
isol
shown
didii
crossreact
poorli
neutral
isol
plasmablast
b
cell
day
wherea
zikv
diii
specif
potent
neutral
isol
memori
b
cell
day
onset
symptom
determin
whether
distinct
featur
could
result
differenti
protect
efficaci
vivo
test
mous
model
defici
ifn
receptor
signal
specif
mice
defici
receptor
mous
challeng
pfu
zikv
strain
via
ip
rout
one
day
challeng
singl
dose
negativecontrol
mab
middl
east
respiratori
syndrom
coronaviru
merscov
administ
via
ip
day
day
challeng
blood
sampl
collect
anim
viral
load
measur
anim
monitor
sign
diseas
surviv
weight
chang
day
shown
figur
anim
treat
negativecontrol
succumb
zikv
infect
averag
time
death
day
respect
sever
weight
loss
also
found
period
figur
contrast
treatment
afford
protect
associ
increas
bodi
weight
day
observ
zikv
rna
load
blood
significantli
higher
anim
figur
result
clearli
demonstr
potent
neutral
rather
poorli
neutral
protect
anim
diseas
may
play
protect
role
studi
subject
natur
infect
report
kinet
antibodi
respons
zikv
natur
infect
convalesc
individu
uniqu
studi
lie
longitudin
approach
character
relat
polyclon
mab
respons
individu
polyclon
antibodi
level
show
rapid
respons
bind
neutral
activ
peak
week
sustain
day
onset
symptom
substanti
degre
crossreact
found
throughout
studi
decompos
bind
respons
didii
diii
e
glycoprotein
show
antibodi
develop
human
follow
spatiotempor
hierarchi
diii
peak
wane
earli
infect
diii
persist
extend
period
time
substanti
degre
crossreact
predominantli
mediat
diii
clear
trend
increas
diiispecif
neutral
activ
observ
cours
infect
although
substanti
portion
neutral
activ
account
antibodi
recogn
complex
quaternari
epitop
compos
one
domain
e
glycoprotein
may
offer
plausibl
explan
mab
level
show
mab
isol
first
week
onset
symptom
larg
target
diii
weakli
neutral
broadli
crossreact
contrast
mab
isol
month
later
expand
specif
includ
didii
diii
didiidiii
potent
neutral
zikv
specif
competit
bind
measur
spr
also
indic
isol
mab
occupi
divers
distinct
epitop
cover
substanti
surfac
e
glycoprotein
interest
note
mab
isol
earli
infect
appear
diverg
germlin
sequenc
later
mab
thorough
studi
would
requir
valid
observ
final
potent
weak
neutral
mab
provid
protect
mice
lethal
zikv
infect
taken
togeth
dynam
featur
unveil
assist
us
better
understand
pathogenesi
zikv
infect
potent
neutral
mab
identifi
provid
promis
candid
antibodybas
intervent
also
inform
epitopefocus
vaccin
design
develop
believ
studi
first
field
delin
longitudin
antibodi
respons
zikv
polyclon
monoclon
level
distinct
dynam
biolog
featur
associ
domainspecif
antibodi
respons
quit
uniqu
perfectli
line
report
denv
infect
well
document
peopl
expos
denv
primari
infect
demonstr
transient
period
broad
protect
heterolog
serotyp
longterm
protect
howev
appear
rel
later
potent
specif
infect
homolog
serotyp
given
identifi
could
hypothes
transient
broad
antibodi
respons
like
mediat
didii
longterm
protect
like
mediat
broader
scope
specif
mab
isol
zikvinfect
individu
other
denvinfect
individu
strongli
support
hypothesi
zikv
didiispecif
mab
predomin
earli
infect
weakli
neutral
broadli
crossreact
didii
fact
mani
mab
crossneutr
effect
zikv
suggest
epitop
may
differenti
expos
access
denv
zikv
context
hand
mab
isol
denv
infect
didii
specif
also
demonstr
strong
crossreact
protect
zikv
furthermor
analysi
sera
individu
acut
denv
infect
show
substanti
capac
bind
neutral
zikv
mirror
found
zikvinfect
patient
respons
denv
current
stage
role
earli
crossreact
didiispecif
mab
vivo
uncertain
could
doubleedg
sword
crossreact
could
certainli
provid
crossprotect
across
zikv
denv
observ
previou
studi
case
futur
therapeut
vaccin
would
need
take
advantag
develop
univers
strategi
zikv
denv
perhap
member
flaviviru
famili
crossreact
could
also
result
crossenhanc
trigger
sever
diseas
human
inde
mani
didii
mab
includ
demonstr
antibodydepend
enhanc
ade
cell
cultur
supplement
figur
anim
model
zikv
denv
infect
whether
enhanc
could
occur
exacerb
diseas
human
would
requir
futur
studi
particular
zikv
denv
continu
cocircul
geograph
region
around
globe
crossenhanc
inde
occur
human
current
vaccin
strategi
would
minim
complet
elimin
didii
would
target
diii
relat
region
instead
potent
neutral
mab
isol
month
onset
symptom
strictli
zikv
specif
cover
distinct
epitop
mere
confin
diii
also
expand
diii
complex
didiidiii
exact
epitop
activ
investig
reason
hypothes
recogn
complex
structur
isol
earlier
infect
crosscompet
mab
multipl
categori
supplement
figur
previou
studi
zikv
denv
infect
identifi
potent
neutral
mab
target
diii
quaternari
epitop
e
glycoprotein
capabl
provid
protect
zikv
infect
diseas
maternalfet
transmiss
mous
model
one
potent
neutral
mab
identifi
also
afford
protect
mice
lethal
zikv
infect
poorli
neutral
didii
crossreact
isol
day
onset
symptom
fail
result
highlight
import
potent
neutral
rather
weakli
nonneutr
mab
provid
protect
zikv
infect
futur
vaccin
strategi
would
focu
induc
class
antibodi
provid
effect
durabl
protect
howev
didiispecif
mab
class
mab
includ
supplement
figur
also
demonstr
ade
suboptim
level
vitro
develop
zikv
vaccin
would
therefor
like
encount
similar
problem
face
denv
vaccin
elicit
suboptim
immun
respons
might
lead
ade
sever
diseas
light
recognit
prophylact
therapeut
intervent
potent
neutral
mab
may
offer
altern
prevent
treatment
zikv
denv
perhap
member
flaviviru
famili
regard
fulli
human
mab
isol
convalesc
human
other
us
repres
promis
altern
gener
natur
infect
expect
minim
antigen
autoreact
human
ensur
safeti
efficaci
futur
engin
mab
elimin
ade
select
mab
combin
synergist
effect
would
certainli
prefer
strategi
final
need
note
studi
mean
perfect
gener
observ
would
need
increas
number
studi
subject
follow
even
longer
time
period
infect
also
didii
diii
express
surfac
yeast
expect
deviat
conform
nativ
e
glycoprotein
intact
virion
cautiou
interpret
data
nevertheless
comprehens
approach
use
provid
addit
insight
complex
dynam
featur
antibodi
respons
zikv
natur
infect
inform
obtain
improv
understand
pathogenesi
zikv
infect
potenti
interplay
denv
flavivirus
alik
potent
neutral
mab
identifi
provid
promis
candid
antibodybas
intervent
also
assist
ration
design
epitopefocus
vaccin
empow
strength
minim
weak
human
immun
recognit
patient
blood
sampl
widespread
epidem
zikv
infect
america
infect
chines
peopl
return
southern
metropolitan
citi
guangzhou
china
sever
affect
south
american
countri
venezuela
surinam
hospit
guangzhou
eighth
peopl
hospit
infect
statu
confirm
rtpcr
posit
zikv
rna
multipl
serum
saliva
urin
sampl
flaviviru
immun
statu
analyz
commerci
avail
kit
diagnosi
zikv
infect
euroimmun
custombas
elisa
built
upon
fulllength
protein
deriv
zikv
isol
china
see
plasma
sampl
rtpcrconfirm
individu
includ
comparison
man
return
venezuela
februari
woman
return
surinam
juli
patient
manifest
rel
mild
symptom
includ
fever
rash
sore
throat
fatigu
recov
discharg
approxim
week
onset
symptom
major
clinic
event
viru
load
serum
urin
kinet
igm
igg
antibodi
respons
previous
report
persist
high
level
zikv
load
urin
found
first
week
onset
symptom
novel
zikv
strain
success
isol
phylogenet
analysi
complet
code
sequenc
indic
genbank
number
tightli
cluster
circul
america
belong
asian
lineag
includ
identifi
french
polynesia
sequenc
analysi
zikv
rna
show
ident
e
region
therefor
fell
asian
lineag
hospit
followup
visit
total
sequenti
blood
sampl
collect
day
collect
day
onset
symptom
collect
blood
sampl
separ
plasma
peripher
blood
mononuclear
cell
pbmc
centrifug
ficollhypaqu
gradient
ge
healthcar
plasma
sampl
heat
inactiv
hour
store
pbmc
maintain
freez
media
store
liquid
nitrogen
use
recombin
zikv
denv
e
glycoprotein
elisa
analysi
recombin
e
glycoprotein
zikv
produc
mammalian
cell
express
system
cterminu
detect
purif
code
sequenc
ectodomain
zikv
e
glycoprotein
obtain
direct
rtpcr
amplif
viral
rna
deriv
either
plasma
sampl
viru
stock
infect
chines
patient
clone
express
vector
invitrogen
approxim
day
transfect
recombin
e
glycoprotein
cultur
supernat
captur
onto
elisa
plate
bind
precoat
antibodi
cliniqa
captur
recombin
e
glycoprotein
use
evalu
plasma
level
antibodi
zikvinfect
patient
screen
presenc
antibodi
cultur
supernat
memori
b
cell
measur
bind
specif
isol
mab
patient
specif
serial
dilut
inactiv
plasma
sampl
isol
mab
zikvinfect
patient
appli
captur
e
glycoprotein
zikv
bind
activ
detect
antihuman
igg
conjug
horseradish
peroxidas
promega
tmb
substrat
cwbio
fulllength
zikv
protein
elisa
analysi
fulllength
protein
zikv
produc
accord
method
describ
cterminu
elisa
analysi
cultur
supernat
transfect
cell
captur
onto
elisa
plate
precoat
antibodi
sequenti
plasma
sampl
serial
dilut
appli
elisa
plate
bind
activ
detect
antihuman
igg
label
hrp
tmb
substrat
serial
dilut
plasma
patient
use
posit
control
isol
zikv
human
mab
plasmablast
memori
b
cell
pbmc
store
liquid
nitrogen
thaw
stain
mixtur
fluorescencelabel
monoclon
antibodi
variou
surfac
maker
igdfitc
igmpb
beckman
coulter
distinguish
plasmablast
igd
igm
high
memori
igd
igm
low
b
cell
subpopul
singl
plasmablast
b
cell
sort
pcr
plate
axygen
contain
icecold
pb
rnase
inhibitor
takara
moflo
astrio
eq
beckman
coulter
plate
seal
store
subject
revers
transcript
superscript
iii
first
strand
synthesi
system
invitrogen
pcr
amplifi
antibodi
heavi
light
variabl
gene
memori
b
cell
approxim
cell
sort
cultur
plate
corn
contain
cultur
medium
clonacellhi
medium
stemcel
technolog
supplement
cpg
odn
invitrogen
inhibitor
sigmaaldrich
ngml
recombin
sino
biolog
inc
irradi
heterolog
human
pbmc
clarifi
cultur
supernat
cell
atcc
contain
infecti
epsteinbarr
viru
approxim
day
later
cell
cultur
supernat
screen
bind
zikv
e
glycoprotein
andor
neutral
activ
zikv
strain
posit
cultur
subject
cellular
rna
extract
revers
transcript
superscript
iii
first
strand
synthesi
system
invitrogen
pcr
amplifi
antibodi
heavi
light
variabl
gene
singl
plasmablast
memori
b
cell
nest
pcr
reaction
perform
use
mixtur
primer
design
amplifi
antibodi
heavi
light
chain
variabl
region
gener
pcr
product
purifi
use
qiaexii
gel
extract
kit
qiagen
clone
backbon
antibodi
express
vector
contain
constant
region
human
pair
antibodi
express
plasmid
transient
transfect
cell
supernat
screen
bind
zikv
e
glycoprotein
neutral
activ
zikv
posit
clone
sequenc
variabl
region
antibodi
heavi
chain
gene
vh
light
chain
gene
vl
analyz
use
imgtvquest
program
manufactur
whole
recombin
human
antibodi
conduct
cell
atcc
transient
transfect
purif
affin
chromatographi
use
protein
agaros
concentr
determin
bca
protein
assay
kit
thermo
fisher
scientif
express
clone
encod
control
antibodi
previous
isol
other
zikv
denvinfect
subject
synthes
confirm
sequenc
product
cell
purifi
protein
chromatograph
control
mab
recogn
flaviviru
group
antigen
provid
jing
capit
medic
univers
beij
china
mab
previous
isol
us
merscov
use
neg
control
plasma
profil
epitop
map
domainspecif
e
glycoprotein
express
yeast
surfac
yeast
clone
express
domainspecif
e
glycoprotein
construct
previous
report
brief
gene
sequenc
encod
diii
diii
zikv
clone
yeast
surfac
display
vector
rational
behind
design
lie
previou
studi
diii
diii
found
structur
independ
connect
poorli
order
moder
conserv
acid
linker
break
point
diii
diii
locat
within
residu
lysin
k
posit
glycin
g
posit
supplement
figur
conserv
among
known
human
flavivirus
zikv
wnv
jev
yfv
tbev
recombin
clone
transform
e
colicompet
cell
amplifi
extract
transform
compet
yeast
cell
line
use
electropor
surfac
express
recombin
diii
diii
yeast
first
grown
sdcaa
media
hour
exponenti
growth
phase
yeast
transfer
sgcaa
media
induct
antigen
express
hour
incub
either
plasma
sampl
mab
subsequ
analysi
specif
induc
yeast
cell
collect
centrifug
g
minut
wash
twice
cold
pb
incub
either
mab
patient
plasma
dilut
ice
hour
occasion
agit
wash
time
cold
pb
cell
incub
pelabel
antihuman
igg
secondari
antibodi
dilut
rabbit
antihuman
iggp
santa
cruz
biotechnolog
inc
ice
addit
hour
wash
pb
time
analyz
fac
calibur
bd
bioscienc
cmyc
protein
tag
cterminu
recombin
diii
diii
use
monitor
express
induct
condit
anticmyc
chicken
igi
dilut
thermo
fisher
scientif
antichicken
igi
fitc
dilut
thermo
fisher
scientif
antibodi
neutral
antibodydepend
enhanc
assay
zikv
hawaii
strain
new
guinea
strain
strain
virus
grown
aed
albopictu
cell
titrat
vero
cell
use
zikv
isol
isol
anoth
import
case
china
wuhan
institut
virolog
chines
academi
scienc
close
relat
strain
circul
america
belong
asian
lineag
includ
strain
identifi
french
polynesia
neutral
assay
serial
dilut
plasma
sampl
mab
mix
zikv
hawaii
strain
new
guinea
strain
hour
appli
vero
cell
cultur
plate
hour
infect
antibodyviru
mixtur
aspir
vero
cell
wash
pb
overlay
dmem
contain
heatinactiv
fb
seaplaqu
agaros
lonza
day
plaqu
stain
crystal
violet
count
manual
antibodydepend
enhanc
assay
serial
dilut
mab
incub
virus
zikv
hour
ad
cell
infect
cell
wash
resuspend
rpmi
medium
supplement
fb
cultur
hour
cell
harvest
intracellularli
stain
panflaviviru
antibodi
provid
jing
capit
medic
univers
denv
especif
antibodi
santa
cruz
biotechnolog
minut
follow
incub
antimous
igg
alexa
fluor
invitrogen
anoth
minut
infect
rate
cell
determin
flow
cytometri
fold
enhanc
analyz
comparison
percentag
infect
cell
presenc
absenc
antibodi
plasma
absorpt
experi
evalu
contribut
domainspecif
antibodi
overal
neutral
activ
plasma
sampl
incub
yeast
clone
express
zikv
envelop
diii
diii
specif
absorb
remov
antibodi
target
region
induc
yeast
clone
centrifug
ad
dilut
plasma
fb
dmem
mixtur
incub
rotari
shaker
overnight
procedur
repeat
sever
time
ad
fresh
yeast
cycl
absorpt
antibodi
respons
detect
correspond
yeast
measur
fac
result
plasma
sampl
adjust
neutral
pb
filter
mm
diamet
filter
corn
evalu
neutral
activ
percent
contribut
calcul
compar
neutral
activ
plasma
sampl
treat
irrelev
yeast
epitop
map
mab
spr
epitop
map
captur
kit
use
accord
manufactur
instruct
ge
antihistidin
antibodi
immobil
sensor
chip
via
amin
group
approxim
zikv
e
protein
inject
ligand
differ
mab
inject
sequenti
monitor
addit
bind
activ
determin
whether
mab
recogn
separ
close
situat
epitop
quantit
measur
viral
genom
taqman
quantit
pcr
total
rna
isol
whole
blood
mous
use
rneasi
mini
kit
qiagen
revers
transcrib
cdna
use
iscript
cdna
synthesi
kit
biorad
viral
genom
quantifi
via
taqman
qpcr
amplif
zikv
gene
primer
probe
use
analysi
shown
follow
zikvf
ccgctgcccaacacaag
zikvr
ccactaacgttcttttgcagacat
zikvprob
agcctaccttgacaagcartcagacactcaa
fam
tamra
assess
therapeut
activ
mab
mice
mice
defici
receptor
mous
purchas
institut
pasteur
shanghai
chines
academi
scienc
mice
bred
maintain
specif
pathogenfre
anim
facil
tsinghua
univers
mice
age
week
challeng
pfu
zikv
strain
via
ip
rout
follow
day
mab
control
antibodi
dilut
pb
administ
via
ip
day
viru
challeng
weight
record
daili
day
day
challeng
blood
collect
anim
viral
load
measur
statist
elisa
analysi
plasma
bind
halfmaxim
effect
concentr
ec
calcul
use
doserespons
stimul
model
graphpad
prism
graphpad
softwar
inc
viru
neutral
assay
ic
mab
calcul
use
doserespons
inhibit
model
graphpad
prism
mice
challeng
protect
experi
statist
signific
analyz
oneway
anova
dunnett
multipl
comparison
test
p
via
graphpad
prism
studi
approv
human
studi
approv
ethic
committe
guangzhou
eighth
peopl
hospit
guangzhou
medic
univers
research
conduct
strict
accord
chines
govern
rule
regul
protect
human
subject
studi
subject
provid
written
inform
consent
research
use
blood
sampl
procedur
anim
undertaken
accord
experiment
anim
welfar
ethic
committe
tsinghua
univers
